Skip Navigation

IID-22 Data Details

IID-22 Increase the number of public health laboratories monitoring influenza virus resistance to antiviral agents

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

National Data Source
State Public Health Laboratories Performing Antiviral Resistance Testing; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (CDC/NCIRD)
Changed Since the Healthy People 2020 Launch
Baseline (Year)
3 (2009)
Target-Setting Method
Maintain consistency with national programs, regulations, policies, and laws.
Number of state public health laboratories that have submitted reports to CDC listing virus susceptibility to either class of antiviral drug (adamantanes or neuraminidase inhibitors)
Data Collection Frequency
Comparable Healthy People 2010 Objective
Not applicable
Methodology Notes

Antivirals are the only prescribed medication available to treat a patient once they have contracted influenza. Monitoring for viruses resistant to antivirals is key to inform prescription and other non-pharmaceutical and pharmaceutical intervention guidance. In 2009, CDC has been the only public health laboratory conducting a comprehensive monitoring of influenza A and B virus susceptibilities to four licensed anti-influenza drugs in the United States.